» Articles » PMID: 18000218

Identification of the Retinoic Acid-inducible Gprc5a As a New Lung Tumor Suppressor Gene

Overview
Specialty Oncology
Date 2007 Nov 15
PMID 18000218
Citations 62
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Lung cancers develop via multiple genetic and epigenetic changes, including inactivation of tumor suppressor genes. We previously cloned human G protein-coupled receptor family C type 5A (GPRC5A), whose expression is suppressed in some human lung carcinoma cells, and its mouse homolog Gprc5a.

Methods: We generated Gprc5a knockout mice by homologous recombination and studied their phenotype by macroscopic observation and microscopic histologic analysis of embryos and lungs of 1- to 2-year-old mice. GPRC5A mRNA expression was analyzed by reverse transcription-polymerase chain reaction in surgical specimens of 18 human lung tumors and adjacent normal tissues and by analyzing previously published data from 186 lung tumor tissues of a variety of histologic types and 17 normal lung samples. Human embryonic kidney, human non-small-cell lung cancer, and mouse lung adenocarcinoma cells were transfected with a GPRC5A expression vector or a control vector, and colony formation in semisolid medium was assayed. Statistical tests were two-sided.

Results: Homozygous knockout mice developed many more lung tumors at 1-2 years of age (incidence: 76% adenomas and 17% adenocarcinomas) than heterozygous (11% adenomas) or wild-type (10% adenomas) mice. Human GPRC5A mRNA levels were lower in most (11 of 18 [61%]) human lung tumors than in adjacent normal tissues. The mean GPRC5A mRNA level in adenocarcinoma (n = 139), squamous cell carcinoma (n = 21), small-cell lung cancer (n = 6), and carcinoid (n = 20) tissues was 46.2% (P = .014), 7.5% (P<.001), 5.3% (P<.001), and 1.8% (P<.001), respectively, that in normal lung tissues (n = 17) GPRC5A transfection suppressed colony formation in semisolid medium of immortalized human embryonic kidney, human non-small-cell lung cancer, and mouse lung adenocarcinoma cells by 91%, 91%, and 68%, respectively, compared with vector controls (all P<.001).

Conclusions: Gprc5a functions as a tumor suppressor in mouse lung, and human GPRC5A may share this property. The Gprc5a-deficient mouse is a novel model to study lung carcinogenesis and chemoprevention.

Citing Articles

NF-κB-mediated EAAT3 upregulation in antioxidant defense and ferroptosis sensitivity in lung cancer.

Wen D, Li W, Song X, Hu M, Liao Y, Xu D Cell Death Dis. 2025; 16(1):124.

PMID: 39987248 PMC: 11847022. DOI: 10.1038/s41419-025-07453-y.


Immunogenic dying cells elicit potent anti-tumor T cell immunity against lung metastasis and tumorigenesis.

Hu M, Meng X, Wang T, Wang Y, Chen X, Xu D J Cancer Res Clin Oncol. 2025; 151(1):38.

PMID: 39825073 PMC: 11741992. DOI: 10.1007/s00432-025-06087-z.


Exploring the Prognostic Value and Immune Infiltration Patterns of GPRC5A Across Multiple Cancer Types.

Hu S, Chen Y, Sun B J Cancer. 2024; 15(14):4749-4758.

PMID: 39006081 PMC: 11242343. DOI: 10.7150/jca.93217.


is a potential prognostic biomarker and correlates with immune cell infiltration in non-small cell lung cancer.

Lin Y, Wang Y, Xue Q, Zheng Q, Chen L, Jin Y Transl Lung Cancer Res. 2024; 13(5):1010-1031.

PMID: 38854942 PMC: 11157364. DOI: 10.21037/tlcr-23-739.


Integrated analysis of scRNA-seq and bulk RNA-seq reveals that GPRC5A is an important prognostic gene in pancreatic cancer and is associated with B-cell Infiltration in pancreatic cancer.

Dong C, Ma H, Mi N, Fu W, Yi J, Gao L Front Oncol. 2024; 14:1283164.

PMID: 38634049 PMC: 11021786. DOI: 10.3389/fonc.2024.1283164.